利伐沙班对比标准抗凝治疗儿童急性静脉血栓栓塞的3期随机对照试验
这项多中心、开放标签、随机3期试验纳入500例0-17岁急性静脉血栓栓塞患儿,按2:1随机接受体重调整利伐沙班或标准抗凝治疗。利伐沙班在儿童中复发风险低且未增加出血。
要点
- 大出血或临床相关非大出血:利伐沙班组3%(均为非大出血),标准抗凝组2%(2例大出血、1例非大出血)。
核心结论
- 在儿童急性静脉血栓栓塞中,利伐沙班较标准抗凝治疗复发风险同样低且降低血栓负荷,未增加出血。
研究设计与样本
- 多中心、平行组、开放标签、随机3期试验,纳入28个国家107家儿科医院的0-17岁急性静脉血栓栓塞患儿,按2:1随机分配至体重调整利伐沙班(20 mg等效剂量)或标准抗凝治疗。
- 筛查520例,入组500例(96%);主要治疗期3个月(<2岁导管相关静脉血栓栓塞患儿为1个月)。
主要发现
- 无治疗相关死亡。
关键数值与推荐
- 主要疗效终点为症状性复发性静脉血栓栓塞(意向治疗分析),主要安全性终点为大出血或临床相关非大出血(接受至少1剂者分析)。
临床怎么用
- 儿童急性静脉血栓栓塞可考虑使用体重调整利伐沙班作为标准抗凝治疗的替代选择,需结合年龄和血栓部位评估。
局限性
- 开放标签设计;主要疗效终点事件数少,置信区间宽;<2岁导管相关静脉血栓栓塞患儿治疗期仅1个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was to compare the efficacy and safety of rivaroxaban versus standard anticoagulants in children with venous thromboembolism. METHODS: In a multicentre, parallel-group, open-label, randomised study, children (aged 0-17 years) attending 107 paediatric hospitals in 28 countries with documented acute venous thromboembolism who had started heparinisation were assigned (2:1) to bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20-mg equivalent dose or standard anticoagulants (heparin or switched to vitamin K antagonist). Randomisation was stratified by age and venous thromboembolism site. The main treatment period was 3 months (1 month in children <2 years of age with catheter-related venous thromboembolism). The primary efficacy outcome, symptomatic recurrent venous thromboembolism (assessed by intention-to-treat), and the principal safety outcome, major or clinically relevant non-major bleeding (assessed in participants who received ≥1 dose), were centrally assessed by investigators who were unaware of treatment assignment. Repeat imaging was obtained at the end of the main treatment period and compared with baseline imaging tests. This trial is registered with ClinicalTrials.gov, number NCT02234843 and has been completed. FINDINGS: From Nov 14, 2014, to Sept 28, 2018, 500 (96%) of the 520 children screened for eligibility were enrolled. After a median follow-up of 91 days (IQR 87-95) in children who had a study treatment period of 3 months (n=463) and 31 days (IQR 29-35) in children who had a study treatment period of 1 month (n=37), symptomatic recurrent venous thromboembolism occurred in four (1%) of 335 children receiving rivaroxaban and five (3%) of 165 receiving standard anticoagulants (hazard ratio [HR] 0·40, 95% CI 0·11-1·41). Repeat imaging showed an improved effect of rivaroxaban on thrombotic burden as compared with standard anticoagulants (p=0·012). Major or clinically relevant non-major bleeding in participants who received ≥1 dose occurred in ten (3%) of 329 children (all non-major) receiving rivaroxaban and in three (2%) of 162 children (two major and one non-major) receiving standard anticoagulants (HR 1·58, 95% CI 0·51-6·27). Absolute and relative efficacy and safety estimates of rivaroxaban versus standard anticoagulation estimates were similar to those in rivaroxaban studies in adults. There were no treatment-related deaths. INTERPRETATION: In children with acute venous thromboembolism, treatment with rivaroxaban resulted in a similarly low recurrence risk and reduced thrombotic burden without increased bleeding, as compared with standard anticoagulants. FUNDING: Bayer AG and Janssen Research & Development.
引用
- Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2019. PMID: 31699660. doi:10.1016/S2352-3026(19)30219-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。